| ARVs included |
Basis MPP’s Priority Document (details in Table 2) |
| Timeline |
2012–2028 |
| Duration of Impact |
Based on projected start—date of impact and expiry date of blocking patents |
| PLHIVs on treatment |
Based on UNAIDS Fast track report [3,4] |
| ARV Market share |
Based on forecasts carried out by the MPP in collaboration with the WHO from 2015 to 2025 [14] |
| Countries included |
Low and Middle income countries as per World Bank |
| Number of countries impacted by licences |
Impact of MPP was attributed to only those countries where the licence had unblocked an existing patent |
| Baseline Price |
Based on originator tiered pricing as per Untangling the Web of Price Reductions by MSF |
| Impacted Price |
Applied an international industry historic average of year-over-year erosion rates of generic product prices |
| Royalty saving |
Basis royalty rates in agreements before and after the MPP licence |
| Net present value |
Discounting factor of 3.5% used to obtain Net Present Value |
| Probability Factor |
Based on the level of negotiations |
| Market Assumptions |
No change in economic environment |
| MPP Operating Cost |
Actual expenses and grant received till date. For years 2021–2028, projected costs are associated only with the management of medicine development projects for ARVs licensed by MPP |
